Bringing breakthroughs to more patients
Bringing breakthroughs to more patients
angilma1
Sun, 09/28/2025 – 21:39
Read more about Bringing breakthroughs to more patients
PrintPDF
This author has yet to write their bio.Meanwhile lets just say that we are proud angilma1 contributed a whooping 20 entries.
Bringing breakthroughs to more patients
angilma1
Sun, 09/28/2025 – 21:39
Read more about Bringing breakthroughs to more patients
PrintPDF
Bringing breakthroughs to more patients
angilma1
Sun, 09/28/2025 – 21:39
Read more about Bringing breakthroughs to more patients
PrintPDF
Vas Narasimhan named to 2025 TIME100 Health list
angilma1
Tue, 05/06/2025 – 15:31
Read more about Vas Narasimhan named to 2025 TIME100 Health list
PrintPDF
Europe talks health sovereignty — now it must deliver
angilma1
Wed, 04/23/2025 – 18:59
Read more about Europe talks health sovereignty — now it must deliver
PrintPDF
Europe talks health sovereignty — now it must deliver
angilma1
Wed, 04/23/2025 – 18:59
Read more about Europe talks health sovereignty — now it must deliver
PrintPDF
Europe talks health sovereignty — now it must deliver
angilma1
Wed, 04/23/2025 – 18:59
Read more about Europe talks health sovereignty — now it must deliver
PrintPDF
Addressing unmet needs for inherited neuromuscular diseases
angilma1
Thu, 11/21/2024 – 12:45
Read more about Addressing unmet needs for inherited neuromuscular diseases
PrintPDF
Negative impact of the IRA on patient access to innovative treatments
angilma1
Thu, 08/15/2024 – 14:46
Read more about Negative impact of the IRA on patient access to innovative treatments
PrintPDF
Negative impact of the IRA on patient access to innovative treatments
angilma1
Thu, 08/15/2024 – 14:46
Read more about Negative impact of the IRA on patient access to innovative treatments
PrintPDF
Novartis statement on Maximum Fair Price for Entresto
angilma1
Thu, 08/15/2024 – 14:36
Read more about Novartis statement on Maximum Fair Price for Entresto
PrintPDF
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
+263 (242) 741 308
+263 (242) 741 309
Mon-Fri: 8am – 5pm
